UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 19, 2021 (February 19, 2021)

CoreCivic, Inc.

(Exact name of registrant as specified in its charter)

Maryland (State or other jurisdiction of incorporation) 001-16109 (Commission File Number) 62-1763875 (I.R.S. Employer Identification No.)

5501 Virginia Way Brentwood, Tennessee (Address of principal executive offices)

37027 (Zip Code)

(615) 263-3000 (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

	ck the appropriate box below if the Form 8-K filing is owing provisions (see General Instruction A.2. below):	3 3	ling obligation of the registrant under any of the
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
	Securities	registered pursuant to Section 12(b) of the	he Act:
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
-	Common Stock	CXW	New York Stock Exchange
	cate by check mark whether the registrant is an emergineter) or Rule 12b-2 of the Securities Exchange Act of 1	1 1	405 of the Securities Act of 1933 (§230.405 of this
			Emerging growth company \Box
	n emerging growth company, indicate by check mark if	-	

Item 8.01 Other Events.

On February 19, 2021, CoreCivic, Inc. (the "Company") announced that Dr. Glenda Baskin Glover ("Dr. Glover") will not serve on the Company's Board of Directors (the "Board"). As reported in the Current Report on Form 8-K filed by the Company on February 19, 2021, Dr. Glover's appointment to the Company's Board was to be effective as of March 1, 2021. On February 19, 2021, Dr. Glover notified the Company that she is unable to join the Board and has declined her appointment as a member of the Board. As a result of Dr. Glover's decision, the size of the Board will remain at eleven.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: February 19, 2021 CORECIVIC, INC.

By: /s/ David Garfinkle

Name: David Garfinkle

Title: Executive Vice President and Chief Financial Officer